RECRUITING

Role of Inflammation in Vascular Phenotype Associated with E-cigarette Use

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.

Official Title

Role of Inflammation in Vascular Phenotype Associated with E-cigarette Use

Quick Facts

Study Start:2024-08-15
Study Completion:2026-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06489249

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 24 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18 - 24 years of age
  2. * no history of e-cigarette use (control) OR current with 6 months or more history of e-cigarette use (chronic use).
  1. * tobacco cigarette use (current or history of)
  2. * use of stimulant drugs
  3. * skin diseases
  4. * cardiovascular disease
  5. * diagnosed or suspected hepatic or metabolic disease including diabetes
  6. * statin or other cholesterol-lowering medication
  7. * antihypertensive medication
  8. * current pregnancy or breastfeeding
  9. * blood pressure greater than or equal to 140mmHg systolic and/or greater than or equal to 90mmHg diastolic
  10. * allergy to materials used during the experiment
  11. * known allergies to salsalate or other study drugs

Contacts and Locations

Study Contact

Anna Stanhewicz, PhD
CONTACT
3194671732
anna-stanhewicz@uiowa.edu

Study Locations (Sites)

Iowa Bioscience Innovation Facility
Iowa City, Iowa, 52242
United States
University of Iowa
Iowa City, Iowa, 52242
United States

Collaborators and Investigators

Sponsor: University of Iowa

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-08-15
Study Completion Date2026-10

Study Record Updates

Study Start Date2024-08-15
Study Completion Date2026-10

Terms related to this study

Additional Relevant MeSH Terms

  • Electronic Cigarette Use
  • Endothelial Dysfunction
  • Inflammation